| 84.07 -0.748 (-0.88%) | 06-12 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 99.55 | 1-year : | 116.27 |
| Resists | First : | 85.23 | Second : | 99.55 |
| Pivot price | 83.17  |
|||
| Supports | First : | 82.12 | Second : | 80.19 |
| MAs | MA(5) : | 83.75 |
MA(20) : | 82.66 |
| MA(100) : | 80.87 |
MA(250) : | 75.69 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 74.9 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 85.63 | Low : | 62.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PBE ] has closed below upper band by 27.0%. Bollinger Bands are 12.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 84.87 - 85.29 | 85.29 - 85.63 |
| Low: | 82.71 - 83.29 | 83.29 - 83.76 |
| Close: | 83.27 - 84.14 | 84.14 - 84.84 |
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.
Fri, 12 Jun 2026
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Yahoo Finance
Wed, 10 Jun 2026
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance
Fri, 05 Jun 2026
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech - The Motley Fool
Thu, 04 Jun 2026
Invesco vs. SPDR Healthcare ETFs: Biotech and Pharma Fund Comparison - News and Statistics - IndexBox
Thu, 04 Jun 2026
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? - The Globe and Mail
Thu, 04 Jun 2026
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|